Osimertinib Mesylate
Brand name: Tagrisso
Rank #43 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$436.5M
Total Cost
25,273
Total Claims
$436.5M
Total Cost
970
Prescribers
$17K
Cost per Claim
972
Beneficiaries
25,504
30-Day Fills
$450K
Avg Cost/Provider
26
Avg Claims/Provider
Share of Medicare Part D Spending
0.16%
of total Medicare Part D spending
$436.5M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $436.5M total
🔎 Data Overview
Ranked #43 out of 500 drugs tracked by total cost. Osimertinib Mesylate represents a significant portion of Medicare drug spending.
At $17,272 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $450,025 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $449,099 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Osimertinib Mesylate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Razmig Babikian | Nurse Practitioner | Duarte, CA | 287 | $5.1M |
| 2 | Norland Ng | Hematology-Oncology | New York, NY | 221 | $3.9M |
| 3 | Shihfan Yeh | Hematology-Oncology | San Antonio, TX | 196 | $3.3M |
| 4 | Jason Kao | Physician Assistant | Stanford, CA | 182 | $3.3M |
| 5 | Kenneth Ng | Medical Oncology | Rockville Centre, NY | 171 | $2.9M |
| 6 | Angela Lu | Nurse Practitioner | Des Moines, IA | 158 | $2.9M |
| 7 | Mark Kris | Medical Oncology | New York, NY | 159 | $2.8M |
| 8 | Amit Arora | Hematology-Oncology | Fremont, CA | 144 | $2.7M |
| 9 | Christina Bi | Pharmacist | Roseville, CA | 156 | $2.6M |
| 10 | Federico Albrecht | Hematology-Oncology | Miami, FL | 152 | $2.6M |
| 11 | Judy Pagtama | Nurse Practitioner | Palo Alto, CA | 153 | $2.6M |
| 12 | Songchuan Guo | Hematology-Oncology | Brooklyn, NY | 143 | $2.6M |
| 13 | Derek Shek | Medical Oncology | San Leandro, CA | 151 | $2.5M |
| 14 | Nagashree Seetharamu | Medical Oncology | New Hyde Park, NY | 129 | $2.5M |
| 15 | Jyoti Patel | Medical Oncology | Chicago, IL | 128 | $2.4M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 40 | Evolocumab (Repatha Sureclick) | $460.5M | 528,560 |
| 41 | Acalabrutinib Maleate (Calquence) | $457.0M | 31,890 |
| 42 | Atorvastatin Calcium (Atorvastatin Calcium) | $444.6M | 30,263,929 |
| 43 | Osimertinib Mesylate (Tagrisso) | $436.5M | 25,273 |
| 44 | Levothyroxine Sodium (Levothyroxine Sodium) | $435.3M | 20,209,418 |
| 45 | Deutetrabenazine (Austedo) | $404.1M | 60,532 |
| 46 | Linagliptin (Tradjenta) | $403.8M | 519,439 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology